Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure−Activity Relationship
Journal of Medicinal Chemistry2004Vol. 47(8), pp. 2075–2088
Citations Over TimeTop 10% of 2004 papers
Stig Jönsson, Gunnar Andersson, Tomas Fex, Tomas Fristedt, Gunnar Hedlund, Karl Jansson, Lisbeth Abramo, Ingela Fritzson, Olga Pekarski, Anna Runström, Helena Sandin, Ingela Τhuvesson, Anders Björk
Abstract
Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).
Related Papers
- → Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis(2006)41 cited
- → Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells(2017)15 cited
- → Synthesis and SAR studies of a novel class of S1P1 receptor antagonists(2007)14 cited
- → Synthesis and biological activity of substance P C-terminal hexapeptide analogues: structure-activity studies(1986)23 cited
- → Microbiome methods in experimental autoimmune encephalomyelitis.(2022)